Richter Gedeon initiated with a Buy at Berenberg

Berenberg analyst Victoria Lambert initiated coverage of Richter Gedeon with a Buy rating and HUF 9,980 price target. The company is best known for its original blockbuster drug Vraylar, which it sells in partnership with AbbVie in the U.S., the analyst tells investors in a research note. The firm says the market is underappreciating the earnings upside potential from Vraylar.